$TVTX
Travere Therapeutics Inc Stock $tvtx

$tvtx Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-K Financial Statement

#000143853320000004 Filed on February 24, 2020

Income Statement

Concept	2019 Q4	2019	2018 Q4
Revenue	$46.69M	$175.3M	$43.77M
YoY Change	6.66%	6.75%	104116.67%
Cost Of Revenue	$1.730M	$5.234M	$1.600M
YoY Change	8.13%	-5.3%	36.75%
Gross Profit	$44.96M	$170.1M	$42.17M
YoY Change	6.62%	7.17%	2.85%
Gross Profit Margin	96.3%	97.01%	96.34%
Selling, General & Admin	$22.71M	$129.0M	$21.54M
YoY Change	5.43%	24.41%	-3.84%
% of Gross Profit	50.51%	75.81%	51.08%
Research & Development	$36.07M	$141.0M	$31.70M
YoY Change	13.79%	13.9%	62.65%
% of Gross Profit	80.23%	82.87%	75.17%
Depreciation & Amortization	$5.290M	$20.41M	$4.880M
YoY Change	8.4%	9.32%	9.42%
% of Gross Profit	11.77%	12.0%	11.57%
Operating Expenses	$63.90M	$269.9M	$48.76M
YoY Change	31.06%	10.49%	-14.99%
Operating Profit	-$28.17M	-$137.4M	-$4.985M
YoY Change	465.04%	71.62%	-67.15%
Interest Expense	-$11.65M	$18.80M	-$2.370M
YoY Change	391.56%	91.84%	-43.97%
% of Operating Profit
Other Income/Expense, Net	-$2.060M	-$9.087M	-$2.470M
YoY Change	-16.6%	-58.37%	-159.68%
Pretax Income	-$30.23M	-$146.4M	-$7.455M
YoY Change	305.46%	43.76%	-32.46%
Income Tax	$32.00K	-$21.00K	$0.00
% Of Pretax Income
Net Earnings	-$30.26M	-$146.4M	-$7.455M
YoY Change	305.89%	42.61%	-57.69%
Net Earnings / Revenue	-64.81%	-83.51%	-17.03%
Basic Earnings Per Share		-$3.46	-$0.18
Diluted Earnings Per Share	-$703.2K	-$3.46	-$0.18
COMMON SHARES
Basic Shares Outstanding	42.96M shares	42.34M shares	41.25M shares
Diluted Shares Outstanding		42.34M shares

Balance Sheet

Concept	2019 Q4	2019	2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$271.9M	$398.5M	$311.3M
YoY Change	-12.66%	-15.48%	39.83%
Cash & Equivalents	$62.44M	$62.40M	$102.9M
Short-Term Investments	$209.5M	$336.1M	$208.5M
Other Short-Term Assets	$6.400M	$6.400M	$5.900M
YoY Change	8.47%	8.47%	-1.67%
Inventory	$6.082M	$6.100M	$5.619M
Prepaid Expenses
Receivables	$18.05M	$18.00M	$12.66M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$429.1M	$429.1M	$495.7M
YoY Change	-13.44%	-13.44%	52.14%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.891M	$9.900M	$3.146M
YoY Change	-8.11%	219.35%	-2.6%
Goodwill	$936.0K		$936.0K
YoY Change	0.0%		0.0%
Intangibles	$157.2M		$186.7M
YoY Change	-15.8%		1.01%
Long-Term Investments	$0.00	$0.00	$15.00M
YoY Change	-100.0%	-100.0%
Other Assets	$14.71M	$7.700M	$7.709M
YoY Change	90.8%	0.0%	38.75%
Total Long-Term Assets	$175.7M	$175.7M	$213.5M
YoY Change	-17.68%	-17.7%	9.74%
TOTAL ASSETS
Total Short-Term Assets	$429.1M	$429.1M	$495.7M
Total Long-Term Assets	$175.7M	$175.7M	$213.5M
Total Assets	$604.8M	$604.8M	$709.2M
YoY Change	-14.72%	-14.72%	36.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$26.61M	$26.60M	$6.954M
YoY Change	282.71%	280.0%	-63.28%
Accrued Expenses	$51.75M	$38.30M	$49.70M
YoY Change	4.13%	15.36%	37.97%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$22.50M
YoY Change	-100.0%	-100.0%
Total Short-Term Liabilities	$95.45M	$95.40M	$104.6M
YoY Change	-8.77%	-8.8%	22.12%
LONG-TERM LIABILITIES
Long-Term Debt	$204.9M	$204.9M	$195.1M
YoY Change	5.02%	5.02%	332.59%
Other Long-Term Liabilities	$20.89M	$83.30M	$17.55M
YoY Change	19.09%	-8.66%	609.75%
Total Long-Term Liabilities	$20.89M	$288.2M	$17.55M
YoY Change	19.09%	0.66%	609.75%
TOTAL LIABILITIES
Total Short-Term Liabilities	$95.45M	$95.40M	$104.6M
Total Long-Term Liabilities	$20.89M	$288.2M	$17.55M
Total Liabilities	$383.6M	$383.6M	$390.9M
YoY Change	-1.87%	-1.87%	72.05%
SHAREHOLDERS EQUITY
Retained Earnings	-$416.4M		-$270.0M
YoY Change	54.23%		51.99%
Common Stock	$636.9M		$589.8M
YoY Change	7.99%		25.01%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$221.2M	$221.2M	$318.3M
YoY Change
Total Liabilities & Shareholders Equity	$604.8M	$604.8M	$709.2M
YoY Change	-14.72%	-14.72%	36.29%

Cashflow Statement

Concept	2019 Q4	2019	2018 Q4
OPERATING ACTIVITIES
Net Income	-$30.26M	-$146.4M	-$7.455M
YoY Change	305.89%	42.61%	-57.69%
Depreciation, Depletion And Amortization	$5.290M	$20.41M	$4.880M
YoY Change	8.4%	9.32%	9.42%
Cash From Operating Activities	-$4.490M	-$58.21M	-$3.570M
YoY Change	25.77%	133.25%	315.12%
INVESTING ACTIVITIES
Capital Expenditures	-$3.980M	$195.0K	-$3.860M
YoY Change	3.11%	-73.18%	31.29%
Acquisitions		$0.00
YoY Change
Other Investing Activities	$5.560M	$35.43M	-$44.94M
YoY Change	-112.37%	-119.3%	-1682.39%
Cash From Investing Activities	$1.580M	$19.86M	-$48.80M
YoY Change	-103.24%	-109.77%	44263.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$0.00
YoY Change		-100.0%
Cash From Financing Activities	90.00K	-$2.077M	520.0K
YoY Change	-82.69%	-100.9%	-62.04%
NET CHANGE
Cash From Operating Activities	-4.490M	-$58.21M	-3.570M
Cash From Investing Activities	1.580M	$19.86M	-48.80M
Cash From Financing Activities	90.00K	-$2.077M	520.0K
Net Change In Cash	-2.820M	-$40.44M	-51.85M
YoY Change	-94.56%	-1262.32%	-13062.5%
FREE CASH FLOW
Cash From Operating Activities	-$4.490M	-$58.21M	-$3.570M
Capital Expenditures	-$3.980M	$195.0K	-$3.860M
Free Cash Flow	-$510.0K	-$58.41M	$290.0K
YoY Change	-275.86%	127.41%	-86.06%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019	dei	Amendment Flag AmendmentFlag	false
CY2019	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019	dei	Entity Central Index Key EntityCentralIndexKey	0001438533
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41389524	shares
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2018Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2019	dei	Document Type DocumentType	10-K
CY2019	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2019	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2019	dei	Entity Shell Company EntityShellCompany	false
CY2019Q2	dei	Entity Public Float EntityPublicFloat	853241144	USD
CY2019	dei	Document Annual Report DocumentAnnualReport	true
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43088921	shares
CY2017	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2019	dei	Document Period End Date DocumentPeriodEndDate	2019-12-31
CY2019	dei	Document Transition Report DocumentTransitionReport	false
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41389524	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43088921	shares
CY2018	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2017	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2017Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	USD
CY2018Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	USD
CY2017	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
CY2018	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
CY2019	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019	dei	Entity File Number EntityFileNumber	001-36257
CY2019	dei	Entity Registrant Name EntityRegistrantName	RETROPHIN, INC.
CY2019	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2019	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-4842691
CY2019	dei	Entity Address Address Line1 EntityAddressAddressLine1	3721 Valley Centre Drive
CY2019	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 200
CY2019	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2019	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2019	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92130
CY2019	dei	City Area Code CityAreaCode	888
CY2019	dei	Local Phone Number LocalPhoneNumber	969-7879
CY2019	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2019	dei	Trading Symbol TradingSymbol	RTRX
CY2019	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2019	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2019	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2019	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	43115508	shares
CY2019Q4	us-gaap	Prepaid Taxes PrepaidTaxes	1395000	USD
CY2019	dei	Entity Small Business EntitySmallBusiness	false
CY2019	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2018Q4	us-gaap	Prepaid Taxes PrepaidTaxes	1716000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	429064000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	62436000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	102873000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	336088000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	368668000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18048000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12662000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	6082000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	5619000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5015000	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4140000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	495678000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2891000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3146000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	14709000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7709000	USD
CY2019Q4	us-gaap	Equity Method Investments EquityMethodInvestments	0	USD
CY2018Q4	us-gaap	Equity Method Investments EquityMethodInvestments	15000000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	157200000	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	186691000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	936000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	936000	USD
CY2019Q4	us-gaap	Assets Assets	604800000	USD
CY2018Q4	us-gaap	Assets Assets	709160000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	26614000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6954000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	51745000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	49695000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	8590000	USD
CY2018Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	6165000	USD
CY2019Q4	rtrx	Acquisition Related Contingent Consideration AcquisitionRelatedContingentConsideration	8500000	USD
CY2018Q4	rtrx	Acquisition Related Contingent Consideration AcquisitionRelatedContingentConsideration	19350000	USD
CY2019Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	0	USD
CY2018Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	22457000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	95449000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	104621000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-416444000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-270017000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	726000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1529000	USD
CY2019Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	204861000	USD
CY2018Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	195091000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	20894000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	17545000	USD
CY2019Q4	rtrx	Acquisition Related Contingent Consideration Noncurrent AcquisitionRelatedContingentConsiderationNoncurrent	62400000	USD
CY2018Q4	rtrx	Acquisition Related Contingent Consideration Noncurrent AcquisitionRelatedContingentConsiderationNoncurrent	73650000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	383604000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	390907000	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	636910000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	589795000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	221196000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	318253000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	604800000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	709160000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	175338000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	164246000	USD
CY2017	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	154937000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5234000	USD
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5527000	USD
CY2017	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3605000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	140963000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	123757000	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	78168000	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	128951000	USD
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	103654000	USD
CY2017	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	101333000	USD
CY2019	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	15051000	USD
CY2018	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	11590000	USD
CY2017	rtrx	Changein Fair Valueof Contingent Consideration ChangeinFairValueofContingentConsideration	19389000	USD
CY2019	us-gaap	Restructuring Charges RestructuringCharges	0	USD
CY2018	us-gaap	Restructuring Charges RestructuringCharges	-242000	USD
CY2017	us-gaap	Restructuring Charges RestructuringCharges	3608000	USD
CY2017	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	2625000	USD
CY2019	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	0	USD
CY2018	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	0	USD
CY2017	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-53791000	USD
CY2019	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	25500000	USD
CY2018	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2019	rtrx	Write Off Of Contingent Consideration WriteOffOfContingentConsideration	18000000	USD
CY2018	rtrx	Write Off Of Contingent Consideration WriteOffOfContingentConsideration	0	USD
CY2017	rtrx	Write Off Of Contingent Consideration WriteOffOfContingentConsideration	0	USD
CY2019	us-gaap	Impairment Of Retained Interest ImpairmentOfRetainedInterest	15000000	USD
CY2018	us-gaap	Impairment Of Retained Interest ImpairmentOfRetainedInterest	0	USD
CY2017	us-gaap	Impairment Of Retained Interest ImpairmentOfRetainedInterest	0	USD
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	312699000	USD
CY2018	us-gaap	Costs And Expenses CostsAndExpenses	244286000	USD
CY2017	us-gaap	Costs And Expenses CostsAndExpenses	208728000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-137361000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-80040000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-314000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-474000	USD
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1107000	USD
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	10055000	USD
CY2018	us-gaap	Investment Income Interest InvestmentIncomeInterest	5499000	USD
CY2017	us-gaap	Investment Income Interest InvestmentIncomeInterest	3234000	USD
CY2019	us-gaap	Interest Expense InterestExpense	18828000	USD
CY2018	us-gaap	Interest Expense InterestExpense	9810000	USD
CY2017	us-gaap	Interest Expense InterestExpense	4422000	USD
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2018	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-17042000	USD
CY2017	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2019	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2018	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2017	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	4491000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9087000	USD
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-21827000	USD
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4572000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-146448000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-101867000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-58363000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-21000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	811000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1368000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-146427000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-102678000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-102678000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	20463000	USD
CY2019	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	2163000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-59731000	USD
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	92000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-59731000	USD
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.46
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.54
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.54
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42339961	shares
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	40433171	shares
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38769816	shares
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-146427000	USD
CY2018	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	39000	USD
CY2017	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-339000	USD
CY2019	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	2163000	USD
CY2018	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-553000	USD
CY2017	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-186000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-144172000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-103192000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-60256000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	307767000	USD
CY2017Q1	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	-4868000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	26645000	USD
CY2017	rtrx	Exercise Of Warrants And Reclassification Of Derivative Liability ExerciseOfWarrantsAndReclassificationOfDerivativeLiability	14866000	USD
CY2017	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-186000	USD
CY2017	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-339000	USD
CY2017	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	8087000	USD
CY2017	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	893000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-59731000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	293134000	USD
CY2018Q1	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	15710000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	19494000	USD
CY2018	rtrx	Exercise Of Warrants And Reclassification Of Derivative Liability ExerciseOfWarrantsAndReclassificationOfDerivativeLiability	5305000	USD
CY2018	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-553000	USD
CY2018	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	39000	USD
CY2018	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	10588000	USD
CY2018	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2269000	USD
CY2018	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	74945000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-102678000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	318253000	USD
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	92000	USD
CY2019	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	1618000	USD
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2444000	USD
CY2019	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	22590000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-146427000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	221196000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-146427000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-102678000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-59731000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	20408000	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	18668000	USD
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	17804000	USD
CY2019	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	0	USD
CY2018	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	0	USD
CY2017	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-6425000	USD
CY2019	rtrx	Increase Decrease In Settlement Expense IncreaseDecreaseInSettlementExpense	0	USD
CY2018	rtrx	Increase Decrease In Settlement Expense IncreaseDecreaseInSettlementExpense	0	USD
CY2017	rtrx	Increase Decrease In Settlement Expense IncreaseDecreaseInSettlementExpense	-2625000	USD
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2018	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-17042000	USD
CY2017	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2019	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	25500000	USD
CY2018	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2017	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2019	rtrx	Provision For Inventory ProvisionForInventory	1468000	USD
CY2018	rtrx	Provision For Inventory ProvisionForInventory	2457000	USD
CY2017	rtrx	Provision For Inventory ProvisionForInventory	609000	USD
CY2019	us-gaap	Impairment Of Retained Interest ImpairmentOfRetainedInterest	15000000	USD
CY2018	us-gaap	Impairment Of Retained Interest ImpairmentOfRetainedInterest	0	USD
CY2017	us-gaap	Impairment Of Retained Interest ImpairmentOfRetainedInterest	0	USD
CY2019	rtrx	Interest Receivablefrom Notes Receivable InterestReceivablefromNotesReceivable	0	USD
CY2018	rtrx	Interest Receivablefrom Notes Receivable InterestReceivablefromNotesReceivable	0	USD
CY2017	rtrx	Interest Receivablefrom Notes Receivable InterestReceivablefromNotesReceivable	651000	USD
CY2019	rtrx	Accretion Expense Contingent Consideration AccretionExpenseContingentConsideration	1485000	USD
CY2018	rtrx	Accretion Expense Contingent Consideration AccretionExpenseContingentConsideration	1357000	USD
CY2017	rtrx	Accretion Expense Contingent Consideration AccretionExpenseContingentConsideration	1723000	USD
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	9903000	USD
CY2018	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3398000	USD
CY2017	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	656000	USD
CY2019	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	788000	USD
CY2018	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-382000	USD
CY2017	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1338000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	21105000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	19774000	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	26874000	USD
CY2019	rtrx	Net Changein Fair Valueof Contingent Consideration NetChangeinFairValueofContingentConsideration	-2948000	USD
CY2018	rtrx	Net Changein Fair Valueof Contingent Consideration NetChangeinFairValueofContingentConsideration	11590000	USD
CY2017	rtrx	Net Changein Fair Valueof Contingent Consideration NetChangeinFairValueofContingentConsideration	19389000	USD
CY2019	rtrx	Business Combination Contingent Consideration Arrangements Changein Amountof Contingent Consideration Payment BusinessCombinationContingentConsiderationArrangementsChangeinAmountofContingentConsiderationPayment	5661000	USD
CY2018	rtrx	Business Combination Contingent Consideration Arrangements Changein Amountof Contingent Consideration Payment BusinessCombinationContingentConsiderationArrangementsChangeinAmountofContingentConsiderationPayment	8085000	USD
CY2017	rtrx	Business Combination Contingent Consideration Arrangements Changein Amountof Contingent Consideration Payment BusinessCombinationContingentConsiderationArrangementsChangeinAmountofContingentConsiderationPayment	3949000	USD
CY2019	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2018	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2017	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	4491000	USD
CY2019	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-112000	USD
CY2018	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-464000	USD
CY2017	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1081000	USD
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	51000	USD
CY2018	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	396000	USD
CY2017	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	83000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5184000	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-152000	USD
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4945000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1958000	USD
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2773000	USD
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1706000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7931000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1358000	USD
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2702000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Taxes IncreaseDecreaseInPrepaidTaxes	-555000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Taxes IncreaseDecreaseInPrepaidTaxes	-1126000	USD
CY2017	us-gaap	Increase Decrease In Prepaid Taxes IncreaseDecreaseInPrepaidTaxes	-621000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	9255000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2708000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2060000	USD
CY2019	rtrx	Increase Decrease In Accrued Expenses And Other Current Liabilities IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities	7943000	USD
CY2018	rtrx	Increase Decrease In Accrued Expenses And Other Current Liabilities IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities	16630000	USD
CY2017	rtrx	Increase Decrease In Accrued Expenses And Other Current Liabilities IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities	596000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-58214000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-24958000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	7403000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	195000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	727000	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	887000	USD
CY2019	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	15370000	USD
CY2018	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	18974000	USD
CY2017	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	13122000	USD
CY2018	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	162755000	USD
CY2019	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0	USD
CY2018	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	15000000	USD
CY2017	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0	USD
CY2019	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	259140000	USD
CY2017	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	114526000	USD
CY2019	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	223712000	USD
CY2018	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	331345000	USD
CY2017	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	102415000	USD
CY2019	rtrx	Proceedsfrom Maturityof Note Receivable ProceedsfromMaturityofNoteReceivable	0	USD
CY2018	rtrx	Proceedsfrom Maturityof Note Receivable ProceedsfromMaturityofNoteReceivable	0	USD
CY2017	rtrx	Proceedsfrom Maturityof Note Receivable ProceedsfromMaturityofNoteReceivable	47500000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	19863000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-203291000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	45602000	USD
CY2019	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	3388000	USD
CY2018	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	9721000	USD
CY2017	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	4099000	USD
CY2019	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	0	USD
CY2018	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	1000000	USD
CY2017	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	852000	USD
CY2019	rtrx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	2084000	USD
CY2018	rtrx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	2000000	USD
CY2017	rtrx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	2000000	USD
CY2019	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	USD
CY2018	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	5305000	USD
CY2017	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	3645000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1618000	USD
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	10588000	USD
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	8087000	USD
CY2019	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	0	USD
CY2018	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	276000000	USD
CY2017	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	0	USD
CY2019	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2018	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	40203000	USD
CY2017	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2019	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	0	USD
CY2018	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	8820000	USD
CY2017	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	0	USD
CY2019	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	1777000	USD
CY2018	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	1714000	USD
CY2017	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	664000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2077000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	231863000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5445000	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-9000	USD
CY2018	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-135000	USD
CY2017	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-58000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-40437000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3479000	USD
CY2017	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	58392000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102873000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	99394000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	41002000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62436000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102873000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	99394000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	7669000	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	1880000	USD
CY2017	us-gaap	Interest Paid Net InterestPaidNet	2070000	USD
CY2019	us-gaap	Income Taxes Paid IncomeTaxesPaid	656000	USD
CY2018	us-gaap	Income Taxes Paid IncomeTaxesPaid	218000	USD
CY2017	us-gaap	Income Taxes Paid IncomeTaxesPaid	7172000	USD
CY2019	rtrx	Reclassification Of Derivative Liability To Equity ReclassificationOfDerivativeLiabilityToEquity	0	USD
CY2018	rtrx	Reclassification Of Derivative Liability To Equity ReclassificationOfDerivativeLiabilityToEquity	0	USD
CY2017	rtrx	Reclassification Of Derivative Liability To Equity ReclassificationOfDerivativeLiabilityToEquity	11221000	USD
CY2019	rtrx	Accrued Royalty In Excess Of Minimum Payable To Sellers AccruedRoyaltyInExcessOfMinimumPayableToSellers	15815000	USD
CY2018	rtrx	Accrued Royalty In Excess Of Minimum Payable To Sellers AccruedRoyaltyInExcessOfMinimumPayableToSellers	14572000	USD
CY2017	rtrx	Accrued Royalty In Excess Of Minimum Payable To Sellers AccruedRoyaltyInExcessOfMinimumPayableToSellers	13247000	USD
CY2019	rtrx	Amendment To Extend Term Of Agreement AmendmentToExtendTermOfAgreement	0	USD
CY2018	rtrx	Amendment To Extend Term Of Agreement AmendmentToExtendTermOfAgreement	0	USD
CY2017	rtrx	Amendment To Extend Term Of Agreement AmendmentToExtendTermOfAgreement	5885000	USD
CY2019	rtrx	Reclassification Of Derivative Liability Of Warrants With Down Round Provisions ReclassificationOfDerivativeLiabilityOfWarrantsWithDownRoundProvisions	0	USD
CY2018	rtrx	Reclassification Of Derivative Liability Of Warrants With Down Round Provisions ReclassificationOfDerivativeLiabilityOfWarrantsWithDownRoundProvisions	15710000	USD
CY2017	rtrx	Reclassification Of Derivative Liability Of Warrants With Down Round Provisions ReclassificationOfDerivativeLiabilityOfWarrantsWithDownRoundProvisions	0	USD
CY2019	us-gaap	Nature Of Operations NatureOfOperations	DESCRIPTION OF BUSINESS<div style="line-height:120%;padding-bottom:4px;padding-top:16px;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Organization and Description of Business</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;text-align:justify;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Retrophin, Inc. (“we”, “our”, “us”, “Retrophin” and the “Company”) refers to Retrophin, Inc., a Delaware corporation, as well as our direct and indirect subsidiaries. Retrophin is a fully integrated biopharmaceutical company headquartered in San Diego, California focused on identifying, developing and delivering life-changing therapies to people with rare diseases. We regularly evaluate and, where appropriate, act on opportunities to expand our product pipeline through licenses and acquisitions of products in areas that will serve patients with serious or rare diseases and that we believe offer attractive growth characteristics. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10.5pt;"><span style="font-family:Arial;font-size:10.5pt;color:#2c2c2c;font-style:italic;font-weight:bold;text-decoration:none;">Clinical Programs</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;text-align:left;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Sparsentan, also known as RE-021, is an investigational product candidate with a dual mechanism of action, a selective endothelin receptor antagonist (“ERA”), with in vitro selectivity toward endothelin receptor type A and a potent angiotensin receptor blocker (“ARB”). Sparsentan is currently being evaluated in two pivotal Phase 3 clinical studies in the following indications:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><span style="font-family:Arial Narrow;font-size:9.5pt;font-weight:bold;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;font-weight:bold;">Focal segmental glomerulosclerosis ("FSGS") </span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">is a rare kidney disease characterized by proteinuria where the glomeruli become progressively scarred. FSGS is a leading cause of end-stage renal disease.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><span style="font-family:Arial Narrow;font-size:9.5pt;font-weight:bold;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;font-weight:bold;">Immunoglobulin A nephropathy ("IgAN")</span><span style="font-family:Arial Narrow;font-size:10pt;font-weight:bold;"> </span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">is an immune-complex-mediated glomerulonephritis characterized by hematuria, proteinuria, and variable rates of progressive renal failure. IgAN is the most common primary glomerular disease.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Chenodal</span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">®</sup></span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> has also been the standard of care for cerebrotendinous xanthomatosis (“CTX”) patients for more than three decades but is not currently labeled for this indication. In January 2020, we randomized the first patients in a Phase 3 clinical trial to evaluate the effects of Chenodal in adult and pediatric patients with CTX. The pivotal study, known as the RESTORE study, is intended to support a new drug application (“NDA”) submission for marketing authorization of Chenodal for CTX in the United States. </span></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10.5pt;"><span style="font-family:Arial;font-size:10.5pt;color:#2c2c2c;font-style:italic;font-weight:bold;text-decoration:none;">Cooperative Research and Development Agreements ("CRADAs"):</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;text-align:left;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company is a participant in two CRADAs, which form a multi-stakeholder approach to pool resources with leading experts, and incorporates the patient perspective early in the identification and development process. Retrophin has partnered with the National Institutes of Health’s National Center for Advancing Translational Sciences ("NCATS") and leading patient advocacy organizations, NGLY1.org and Alagille Syndrome Alliance ("ALGSA"), aimed at the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome, respectively. There are no treatment options currently approved for these diseases.</span></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10.5pt;"><span style="font-family:Arial;font-size:10.5pt;color:#2c2c2c;font-style:italic;font-weight:bold;text-decoration:none;">Approved products:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:16px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Chenodal (chenodiol tablets) is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has been the standard of care for CTX patients for more than three decades.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Cholbam</span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">®</sup></span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> (cholic acid capsules) is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:16px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Thiola</span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">®</sup></span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> and Thiola EC</span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">®</sup></span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> (tiopronin tablets) are approved in the United States for the </span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:12px;font-size:10.5pt;"><span style="font-family:Arial;font-size:10.5pt;color:#2c2c2c;font-style:italic;font-weight:bold;text-decoration:none;">Changes in Development Activities:</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;text-align:left;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In August 2019, the Company announced that the Phase 3 FORT Study evaluating the safety and efficacy of fosmetpantotenate compared to placebo in patients with pantothenate kinase-associated neurodegeneration ("PKAN") did not meet its primary endpoint and did not demonstrate a difference between treatment groups. The study also did not meet its secondary endpoint. The Company will not proceed with further development of fosmetpantotenate for PKAN.</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;text-align:left;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In August 2019, following a strategic review of the CNSA-001 program in patients with phenylketonuria ("PKU"), the Company made the decision to decline to exercise its option to acquire Censa Pharmaceuticals and accordingly discontinue its joint development program for CNSA-001. The Company impaired the related </span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"><span>$15</span></span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> million long-term investment during the third quarter of 2019.</span></div><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">During the first quarter of 2019, the Company elected to discontinue development of the L-UDCA program, resulting in impairment of the intangible asset of </span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"><span>$25.5 million</span></span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">, originally recorded in 2016, and the related </span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"><span>$18.0 million</span></span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"> in contingent liability. This resulted in a net </span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;"><span>$7.5 million</span></span> non-cash charge to first quarter operations.
CY2019Q3	us-gaap	Impairment Of Retained Interest ImpairmentOfRetainedInterest	15000000	USD
CY2019Q1	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-7500000	USD
CY2019	us-gaap	Use Of Estimates UseOfEstimates	<div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Use of Estimates</span></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;text-align:left;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In preparing financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include revenue recognition, valuing equity securities in share-based payments, estimating expenses of contracted research organizations, estimating fair value of equity instruments recorded as derivative liabilities, estimating the useful lives of depreciable and amortizable assets, goodwill impairment, estimating the fair value of contingent consideration, estimating of valuation allowances and uncertain tax positions, and estimates associated with the assessment of impairment for long-lived assets.</span></div>
CY2019	rtrx	Number Of Phase Three Clinical Trials NumberOfPhaseThreeClinicalTrials	3	clinical_trial
CY2019	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	100000	USD
CY2018	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2019Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	3100000	USD
CY2018Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1800000	USD
CY2017	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	200000	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2019Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2713000	USD
CY2018Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2883000	USD
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3369000	USD
CY2018Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2736000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	6082000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	5619000	USD
CY2019	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2019	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2019	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	reporting_unit
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2018	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2019	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="line-height:120%;padding-bottom:8px;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:Arial Narrow;font-size:10pt;color:#00497f;font-style:normal;font-weight:bold;text-decoration:none;">Reclassifications</span><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"> </span></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;text-align:justify;font-size:9.5pt;"><span style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Certain reclassifications have been made to the prior year financial statements in order to conform to the current year’s presentation.</span></div>
CY2019	rtrx	Common Stock Number Of Tranches CommonStockNumberOfTranches	5	tranche
CY2018Q1	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	15700000	USD
CY2018	us-gaap	Restructuring Reserve Accrual Adjustment1 RestructuringReserveAccrualAdjustment1	200000	USD
CY2017	us-gaap	Restructuring Reserve Accrual Adjustment1 RestructuringReserveAccrualAdjustment1	3600000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	175338000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	164246000	USD
CY2017	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	154937000	USD
CY2018Q1	us-gaap	Cost Method Investments CostMethodInvestments	15000000.0	USD
CY2019Q3	us-gaap	Impairment Of Retained Interest ImpairmentOfRetainedInterest	15000000	USD
CY2018Q1	rtrx	Business Combination Option Agreement Purchase Price BusinessCombinationOptionAgreementPurchasePrice	65000000.0	USD
CY2018Q1	rtrx	Business Combination Option Agreement Purchase Price Percent Transferred In Cash BusinessCombinationOptionAgreementPurchasePricePercentTransferredInCash	0.20
CY2018Q1	rtrx	Business Combination Option Agreement Purchase Price Percent Transferred By Issuance Of Equity BusinessCombinationOptionAgreementPurchasePricePercentTransferredByIssuanceOfEquity	0.80
CY2018Q1	rtrx	Business Combination Option Agreement Share Price BusinessCombinationOptionAgreementSharePrice	21.40
CY2018Q1	rtrx	Business Combination Option Agreement Percent Of Consideration Paid In Cash If Share Price Falls Below Share Price Threshold BusinessCombinationOptionAgreementPercentOfConsiderationPaidInCashIfSharePriceFallsBelowSharePriceThreshold	1
CY2018Q1	rtrx	Business Combination Option Agreement Contingent Consideration BusinessCombinationOptionAgreementContingentConsideration	25000000.0	USD
CY2019Q1	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	25500000	USD
CY2019Q1	rtrx	Write Off Of Contingent Consideration WriteOffOfContingentConsideration	18000000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	336088000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	368668000	USD
CY2017	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	114500000	USD
CY2019Q4	rtrx	Debt Securities Availableforsale Amortized Cost Basis Current DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent	208906000	USD
CY2019Q4	rtrx	Debt Securities Available For Sale Unrealized Gain Current DebtSecuritiesAvailableForSaleUnrealizedGainCurrent	598000	USD
CY2019Q4	rtrx	Debt Securities Available For Sale Unrealized Loss Current DebtSecuritiesAvailableForSaleUnrealizedLossCurrent	10000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	209494000	USD
CY2019Q4	rtrx	Debt Securities Availableforsale Amortized Cost Basis Noncurrent DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent	126300000	USD
CY2019Q4	rtrx	Debt Securities Available For Sale Unrealized Gain Noncurrent DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent	351000	USD
CY2019Q4	rtrx	Debt Securities Available For Sale Unrealized Loss Noncurrent DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent	57000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	126594000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	335206000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	949000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	67000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	336088000	USD
CY2018Q4	rtrx	Debt Securities Availableforsale Amortized Cost Basis Current DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent	209137000	USD
CY2018Q4	rtrx	Debt Securities Available For Sale Unrealized Gain Current DebtSecuritiesAvailableForSaleUnrealizedGainCurrent	0	USD
CY2018Q4	rtrx	Debt Securities Available For Sale Unrealized Loss Current DebtSecuritiesAvailableForSaleUnrealizedLossCurrent	662000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	208475000	USD
CY2018Q4	rtrx	Debt Securities Availableforsale Amortized Cost Basis Noncurrent DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent	160810000	USD
CY2018Q4	rtrx	Debt Securities Available For Sale Unrealized Gain Noncurrent DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent	22000	USD
CY2018Q4	rtrx	Debt Securities Available For Sale Unrealized Loss Noncurrent DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent	639000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	160193000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	369947000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	22000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1301000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	368668000	USD
CY2019	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	259100000	USD
CY2018	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	162800000	USD
CY2018Q3	us-gaap	Debt Instrument Repurchase Amount DebtInstrumentRepurchaseAmount	23400000	USD
CY2019	us-gaap	Debt Instrument Convertible Threshold Percentage Of Stock Price Trigger DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger	1.30
CY2019Q4	rtrx	Debt Instrument Convertible Note Market Price Per1000 DebtInstrumentConvertibleNoteMarketPricePer1000	775	USD
CY2019Q4	rtrx	Debt Conversion Liability DebtConversionLiability	198600000	USD
CY2019	rtrx	Debt Conversion Equity DebtConversionEquity	77400000	USD
CY2019Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	8800000	USD
CY2019Q4	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.077
CY2018Q3	us-gaap	Debt Instrument Repurchase Amount DebtInstrumentRepurchaseAmount	23400000	USD
CY2019Q2	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	1300000	shares
CY2019	us-gaap	Interest Expense InterestExpense	18800000	USD
CY2018	us-gaap	Interest Expense InterestExpense	9800000	USD
CY2017	us-gaap	Interest Expense InterestExpense	4400000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	62436000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	336088000	USD
CY2019Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	398524000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	70900000	USD
CY2019Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	70900000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	102873000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	368668000	USD
CY2018Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	471541000	USD
CY2018Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	93000000	USD
CY2018Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	93000000	USD
CY2019Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	245802000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	88602000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	157200000	USD
CY2018Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	255643000	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	68952000	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	186691000	USD
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019	rtrx	Common Stock Voting Rights Number Of Votes CommonStockVotingRightsNumberOfVotes	1	vote
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018Q4	us-gaap	Share Price SharePrice	22.63
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4834781	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	16.81
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y11M23D
CY2018Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	35387000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4936995	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	18.93
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y7M13D
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	4490000	USD
CY2019Q4	us-gaap	Share Price SharePrice	14.20
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	19707000	USD
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	18028000	USD
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	17331000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	20773000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	20773000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	20739000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	20449000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	19543000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	54923000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	157200000	USD
CY2019Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	14045000	USD
CY2018Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	10446000	USD
CY2019Q4	rtrx	Accrued Liabilities Researchand Development Current AccruedLiabilitiesResearchandDevelopmentCurrent	16067000	USD
CY2018Q4	rtrx	Accrued Liabilities Researchand Development Current AccruedLiabilitiesResearchandDevelopmentCurrent	16515000	USD
CY2019Q4	rtrx	Accrued Government Rebate Reserves AccruedGovernmentRebateReserves	6584000	USD
CY2018Q4	rtrx	Accrued Government Rebate Reserves AccruedGovernmentRebateReserves	8464000	USD
CY2019Q4	rtrx	Accrued Liabilities Selling Generaland Administrative Current AccruedLiabilitiesSellingGeneralandAdministrativeCurrent	3552000	USD
CY2018Q4	rtrx	Accrued Liabilities Selling Generaland Administrative Current AccruedLiabilitiesSellingGeneralandAdministrativeCurrent	2990000	USD
CY2019Q4	rtrx	Accrued Royaltyand Contingent Consideration AccruedRoyaltyandContingentConsideration	7272000	USD
CY2018Q4	rtrx	Accrued Royaltyand Contingent Consideration AccruedRoyaltyandContingentConsideration	6805000	USD
CY2019Q4	rtrx	Accrued Liabilities Miscellaneous AccruedLiabilitiesMiscellaneous	4225000	USD
CY2018Q4	rtrx	Accrued Liabilities Miscellaneous AccruedLiabilitiesMiscellaneous	4475000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	51745000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	49695000	USD
CY2017Q4	us-gaap	Share Price SharePrice	21.07
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21105000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19774000	USD
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	26874000	USD
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42339961	shares
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-146427000	USD
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.46
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	40433171	shares
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-102678000	USD
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.54
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38769816	shares
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-59731000	USD
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.54
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	15875963	shares
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16299349	shares
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11039901	shares
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-146448000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-101867000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-58363000	USD
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	811000	USD
CY2017	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	7793000	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-319000	USD
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	698000	USD
CY2017	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	6991000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	298000	USD
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	113000	USD
CY2017	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	802000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-21000	USD
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-7965000	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	1540000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-6425000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-21000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	811000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1368000	USD
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3500
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0435
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0444
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0330
CY2019	rtrx	Change In Fv Of Derivative Liability Warrants ChangeInFvOfDerivativeLiabilityWarrants	0
CY2018	rtrx	Change In Fv Of Derivative Liability Warrants ChangeInFvOfDerivativeLiabilityWarrants	0
CY2017	rtrx	Change In Fv Of Derivative Liability Warrants ChangeInFvOfDerivativeLiabilityWarrants	-0.0282
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.2329
CY2019	rtrx	Effective Income Tax Rate Reconciliation Non Taxable Bargain Purchase Gain EffectiveIncomeTaxRateReconciliationNonTaxableBargainPurchaseGain	0
CY2018	rtrx	Effective Income Tax Rate Reconciliation Non Taxable Bargain Purchase Gain EffectiveIncomeTaxRateReconciliationNonTaxableBargainPurchaseGain	-0.2177
CY2017	rtrx	Effective Income Tax Rate Reconciliation Non Taxable Bargain Purchase Gain EffectiveIncomeTaxRateReconciliationNonTaxableBargainPurchaseGain	0
CY2019	rtrx	Effective Income Tax Rate Reconciliation Loss On Extinguishment Of Debt Percent EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebtPercent	0
CY2018	rtrx	Effective Income Tax Rate Reconciliation Loss On Extinguishment Of Debt Percent EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebtPercent	0.0409
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	14715000	USD
CY2019Q4	rtrx	Deferred Tax Assets Contingent Consideration DeferredTaxAssetsContingentConsideration	18029000	USD
CY2018Q4	rtrx	Deferred Tax Assets Contingent Consideration DeferredTaxAssetsContingentConsideration	23459000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	4319000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	3710000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	19458000	USD
CY2017	rtrx	Effective Income Tax Rate Reconciliation Loss On Extinguishment Of Debt Percent EffectiveIncomeTaxRateReconciliationLossOnExtinguishmentOfDebtPercent	0
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.0024
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.0010
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.0104
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.1517
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.1186
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.0579
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0044
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0142
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0348
CY2019	rtrx	Other Federal Income Tax Expense OtherFederalIncomeTaxExpense	-0.0232
CY2018	rtrx	Other Federal Income Tax Expense OtherFederalIncomeTaxExpense	-0.0106
CY2017	rtrx	Other Federal Income Tax Expense OtherFederalIncomeTaxExpense	-0.0125
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.3750
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.0979
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2162
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0002
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0093
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0245
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	27747000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9700000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	33315000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	16761000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	1256000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0	USD
CY2018Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	555000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	104124000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	68900000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	2749000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	14288000	USD
CY2019Q4	rtrx	Deferred Tax Liabilities Deferred Gainon Installment Sale DeferredTaxLiabilitiesDeferredGainonInstallmentSale	16182000	USD
CY2018Q4	rtrx	Deferred Tax Liabilities Deferred Gainon Installment Sale DeferredTaxLiabilitiesDeferredGainonInstallmentSale	18419000	USD
CY2019Q4	rtrx	Deferred Tax Liabilities Tax Basis Depreciation Lessthan Book Depreciation DeferredTaxLiabilitiesTaxBasisDepreciationLessthanBookDepreciation	448000	USD
CY2019Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	USD
CY2018Q4	rtrx	Deferred Tax Liabilities Tax Basis Depreciation Lessthan Book Depreciation DeferredTaxLiabilitiesTaxBasisDepreciationLessthanBookDepreciation	0	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	19379000	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	32707000	USD
CY2019Q4	rtrx	Deferred Tax Assets Liabilities Net Before Valuation Allowance DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance	84745000	USD
CY2018Q4	rtrx	Deferred Tax Assets Liabilities Net Before Valuation Allowance DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance	36194000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	84745000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	36194000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2018Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	84700000	USD
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	48600000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	200000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	235000	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2018	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	235000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2017Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	15700000	USD
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares
CY2018	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	900000	USD
CY2017	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	600000	USD
CY2019	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1000000.0	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4731000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4284000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1840000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1138000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2891000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3146000	USD
CY2019	us-gaap	Depreciation Depreciation	700000	USD
CY2018	us-gaap	Depreciation Depreciation	600000	USD
CY2017	us-gaap	Depreciation Depreciation	500000	USD
CY2016Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P7Y7M
CY2016Q3	rtrx	Operating Lease Incentive Tenant Improvements OperatingLeaseIncentiveTenantImprovements	2300000	USD
CY2016Q3	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	14000000.0	USD
CY2019Q1	rtrx	Operating Lease Incentive Tenant Improvements OperatingLeaseIncentiveTenantImprovements	1800000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.077
CY2019Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y7M
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7900000	USD
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	11300000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2613000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2486000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2561000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2637000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1584000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	0	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	11881000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1874000	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	10007000	USD
CY2019Q4	rtrx	Operating Lease Incentive Tenant Improvements OperatingLeaseIncentiveTenantImprovements	1463000	USD
CY2019Q4	rtrx	Straight Line Lease Expense In Excess Of Cash Payments StraightLineLeaseExpenseInExcessOfCashPayments	1549000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6995000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7000000.0	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2613000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	7394000	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	10007000	USD
CY2019	us-gaap	Operating Lease Expense OperatingLeaseExpense	2700000	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	1710000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	11717000	USD
CY2019Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	46688000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	44373000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	44707000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	39570000	USD
CY2019Q4	us-gaap	Costs And Expenses CostsAndExpenses	74855000	USD
CY2019Q3	us-gaap	Costs And Expenses CostsAndExpenses	78810000	USD
CY2019Q2	us-gaap	Costs And Expenses CostsAndExpenses	81236000	USD
CY2019Q1	us-gaap	Costs And Expenses CostsAndExpenses	77798000	USD
CY2019Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-28167000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-34437000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-36529000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-38228000	USD
CY2019Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2060000	USD
CY2019Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2576000	USD
CY2019Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2103000	USD
CY2019Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2348000	USD
CY2019Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-30227000	USD
CY2019Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-37013000	USD
CY2019Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-38632000	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-40576000	USD
CY2019Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	32000	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-523000	USD
CY2019Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	69000	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	401000	USD
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	-30259000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-36490000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-38701000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-40977000	USD
CY2019Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.70
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.85
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.92
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.99
CY2018Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	43771000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	40706000	USD
CY2018Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	41337000	USD
CY2018Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	38432000	USD
CY2018Q4	us-gaap	Costs And Expenses CostsAndExpenses	48756000	USD
CY2018Q3	us-gaap	Costs And Expenses CostsAndExpenses	76289000	USD
CY2018Q2	us-gaap	Costs And Expenses CostsAndExpenses	62897000	USD
CY2018Q1	us-gaap	Costs And Expenses CostsAndExpenses	56344000	USD
CY2018Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-4985000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-35583000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-21560000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-17912000	USD
CY2018Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2470000	USD
CY2018Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-18518000	USD
CY2018Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-602000	USD
CY2018Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-237000	USD
CY2018Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7455000	USD
CY2018Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-54101000	USD
CY2018Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-22162000	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18149000	USD
CY2018Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	415000	USD
CY2018Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	167000	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	229000	USD
CY2018Q4	us-gaap	Net Income Loss NetIncomeLoss	-7455000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-54516000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-22329000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-18378000	USD
CY2018Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.34
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.56
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.46
CY2019Q3	us-gaap	Impairment Of Retained Interest ImpairmentOfRetainedInterest	15000000	USD
CY2019Q1	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-7500000	USD

Files In Submission

Name	View Source	Status
0001438533-20-000004-index-headers.html	Edgar Link	pending
0001438533-20-000004-index.html	Edgar Link	pending
0001438533-20-000004.txt	Edgar Link	pending
0001438533-20-000004-xbrl.zip	Edgar Link	pending
cooleygraphica01.jpg	Edgar Link	pending
equitychart12312019.jpg	Edgar Link	pending
ex1037-1231201910k.htm	Edgar Link	pending
ex11-1231201910k.htm	Edgar Link	pending
ex211-1231201910k.htm	Edgar Link	pending
ex231-1231201910k.htm	Edgar Link	pending
ex311-1231201910k.htm	Edgar Link	pending
ex312-1231201910k.htm	Edgar Link	pending
ex321-1231201910k.htm	Edgar Link	pending
ex322-1231201910k.htm	Edgar Link	pending
ex42-1231201910k.htm	Edgar Link	pending
ex511231201910k.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
productpipelineq419a01.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
rtrx-20191231.xsd	Edgar Link	pending
rtrx-20191231x10k.htm	Edgar Link	pending
rtrx-20191231x10k_htm.xml	Edgar Link	completed
rtrx-20191231_cal.xml	Edgar Link	unprocessable
rtrx-20191231_def.xml	Edgar Link	unprocessable
rtrx-20191231_lab.xml	Edgar Link	unprocessable
rtrx-20191231_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TVTX
Travere Therapeutics Inc Stock $tvtx

2019 Q4 Form 10-K Financial Statement

#000143853320000004 Filed on February 24, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVTX Travere Therapeutics Inc Stock $tvtx

2019 Q4 Form 10-K Financial Statement

#000143853320000004 Filed on February 24, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVTX
Travere Therapeutics Inc Stock $tvtx